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PCR detected EIAV nucleic acid in 31/56 AGID positive samples,
while 108/109 AGID negative samples tested negative by iiRT-
PCR. Total agreement was 84.24%. When whole blood samples
were evaluated, a total of 16 iiRT-PCR positive and 15 iiRT-PCR
negative out of 31 AGID positive samples were obtained. Addi-
tionally, EIAV nucleic acid was not detected in 25 AGID negative
samples .Total agreement was 73.21% for this sample type. When
evaluating the accuracy of EIAV iiRT-PCR and qPCR, 28/165 and
130/165 buffy coat samples tested positive and negative by both
assays, respectively. Five iiRT-PCR positive samples were negative
by qPCR and two qPCR positive samples were negative by iiRT-
PCR. Thus, EIAV iiRT-PCR showed more than 95% agreement with
qPCR results. It has been demonstrated that the absence of clinical
signs is correlated with very low, frequently undetectable
viremia. Therefore, EIAV iiRT-PCR appears to be a promising tool
to identify infected horses including those experiencing low
infectivity titers in blood. Furthermore, as initial EIAV replication
rates are frequently high, recently infected equids pose a
considerable transmission risk long before seroconversion. In our
study, a horse was determined seronegative by AGID, but was
identiﬁed as EIAV infected by iiRT-PCR. Thus, EIAV iiRT-PCR could
be considered as an alternative diagnostic tool in the imple-
mentation of control strategies during an EIA outbreak in the low
prevalence area of our country.
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Equine arteritis virus (EAV) is the cause of equine viral arteritis,
a systemic viral disease of equids that is characterized by signsTable 1
Diagnostic performance of previous EAV ELISAs
Assay format, number sera tested Diagnostic sensitivity Diagnostic speciﬁcity Reference
Indirect ELISA (gp5+N+M), 187 92.3, 57.1% 100% J Virol Methods 76:127-37
Indirect ELISA (peptide, N and replicase), 200 99% 71% J Virol Methods 73:175-83
Indirect ELISA (WV), 839 87.5% 98.9% J Vet Med Sci 60:1043-5
Indirect ELISA (gp5), 1500 99.6% 90.1% J Virol Methods 54:1-13
Indirect ELISA (WV), 46 96% 26% Equin Vet J 40(2):182-3
Competitive blocking ELISA (M), 100 86% 100% CIMID. 26:251-60
Indirect ELISA (gp5), 800 96.75% 95.8% J Virol Methods 90:167-83
Competitive blocking ELISA (gp5), 675 90.7% 99% CJVR;64:38-43of respiratory disease, abortion, and infrequently, death in
young foals. OIE deﬁnes a horse as seropositive if its EAV virus
neutralization (VN) antibody titer is 1:4. The VN test can take
up to 72 hours to complete and requires certain laboratory fa-
cilities, equipment, and technical expertise to perform. Non-
viral cytotoxicity of sera from some horses vaccinated with
certain equine herpesvirus-1 vaccines can interfere with
interpretation of the test. Inter-laboratory variation in VN re-
sults due to variables such as reference virus used, type and cell
passage history has been reported. For these reasons an alter-
native serologic test is desirable, but none of the previously
reported ELISA tests (Table 1) have shown equivalent sensitivityand speciﬁcity compared to the VN test. With the aim of pro-
ducing a simpler and faster alternative to the OIE-prescribed
test, a cELISA was developed using EAV gp5-speciﬁc non-
neutralizing monoclonal antibody (MAb) 17B7. This cELISA was
validated with diverse sera (n¼2469) against the VN test. It had
a diagnostic sensitivity of 95.5% and a diagnostic speciﬁcity of
99.8% (JVDI. 25:182-8). The MAb-17B7 cELISA was further
validated in three EAV-testing laboratories including one OIE-
reference and two AAVLD-accredited laboratories: These
conﬁrmed a test sensitivity of 99.5% and a speciﬁcity of 98.2%
(JVDI 25:727-35). As part of test validation, the following ﬁve
additional analyses were satisfactorily performed according to
the OIE-recommended validation protocol: 1. the primary assay
was calibrated with the OIE approved reference serum panel for
EVA, 2. repeatability of the assay was evaluated within and
between runs, 3. analytical speciﬁcity was evaluated using sera
speciﬁc for selected equine viruses, 4. analytical sensitivity was
evaluated with sera collected from horses vaccinated with the
modiﬁed live virus vaccine against EVA (Arvac®, Zoetis Animal
Health), and 5. Duration of the positive cELISA antibody was
evaluated following EVA vaccination. The analytical sensitivity
of the new cELISA was comparable to the VN test in that it
detected EAV-speciﬁc antibody as early as 6 days post-vacci-
nation. The duration of EAV-speciﬁc antibody detection by
cELISA was over six years post-vaccination. Based on the data
obtained, signiﬁcant correlation was demonstrated between
the VN test and cELISA results (r2¼0.79, P<0.0001). The cELISA
was further improved using EAV puriﬁed by anion-exchange
membrane chromatography (JVDI accepted). This enhanced
cELISA was validated using diverse sera (n¼3255) at the
Maxwell H. Gluck Equine Research Center. The relative sensi-
tivity and speciﬁcity of this assay against a group of ﬁeld sera
(n¼1851) was 99.6% (95% CI 99.4-100.0) and 98.7% (95% CI 98.3,
99.6), respectively, compared to the VN test (manuscript sub-
mitted). This rapid, highly sensitive and speciﬁc cELISA com-
pares very favorably to the VN test. It is USDA licensed and
should facilitate screening of horses intended for international
movement.045
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West Nile virus (WNV), Japanese encephalitis virus (JEV) and tick-
borne encephalitis virus (TBEV) are ﬂaviviruses responsible for
severe neuro-invasive infections in horses and humans. The
conﬁrmation of ﬂavivirus infections is mostly based on rapid
serological tests such as enzyme-linked immunosorbent assays
(ELISA). These tests suffer from poor speciﬁcity, mainly due to
antigenic cross-reactivity among ﬂavivirus members. Robust
diagnosis therefore needs to be validated through virus neutral-
isation tests (VNT) which are time-consuming and require BSL3
facilities. The ﬂavivirus envelope (E) glycoprotein ectodomain is
composed of three domains (D), e.g. DI, DII and DIII, with EDIII
containing virus-speciﬁc epitopes. In order to improve the sero-
logical differentiation of ﬂavivirus infections, the recombinant
soluble ectodomain of WNV E (WNV.sE) and EDIIIs (rEDIIIs) of
WNV, JEV and TBEV were synthesised using the Drosophila S2
expression system. Puriﬁed antigens were covalently bonded to
ﬂuorescent beads (ﬁgure 1). The microspheres coupled with
WNV.sE or rEDIIIs were assayed with about 300 equine immune
sera from natural and experimental ﬂavivirus infections and 172
non-immune equine sera as negative controls. rEDIII-coupled
microspheres captured speciﬁc antibodies against WNV, TBEV or
JEV in positive horse sera in a ﬂavivirus multiplex immunoassay
(MIA). MIA developed for the detection of ﬂavirus infection
showed a relative sensitivity and speciﬁcity close to 99% when
compared to ﬂavivirus competition ELISA. By comparison with
VNT, ﬂavivirus MIA correctly identiﬁed the causative ﬂavivirus in
100%, 96.8% and 90.0% WNV-, TBEV- and JEV-infected horses
respectively. Several advantages plead in favour of the develop-
ment and implementation of this ﬂavivirus MIA in reference
laboratories: no need for BSL3 facilities to conﬁrm ﬂavivirus in-
fections , requirement of small sampling volumes (1 ml) as well as
analysis speed-up (< 3hours).
Figure 1. Presentation of the ﬂavivirus MIA with four beads coupled to four
antigens (WNV.sE, WNV.EDIII, JEV.EDIII and TBEV.EDIII)
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VS is a zoonotic viral disease affecting livestock. The causa-
tive agent, Vesicular Stomatitis virus (VSV), belongs to the
genus Vesiculovirus in Rhabdoviridae family. Two serotypes
have been described: New Jersey (NJ) and Indiana (IND), the
latter being subdivided into 3 subtypes (Indiana 1, 2, 3). In
cattle and pigs, VS remains clinically difﬁcult to differentiate
from foot and mouth disease (FMD) when horses are not
involved. A prompt laboratory differential diagnosis is thus
essential. Serological diagnosis is based on VNT, Complement
Fixation and ELISA. This study describes the development of a
rapid serological diagnostic test based on Luminex technol-
ogy and its comparison with the VNT and Competitive ELISA
(C ELISA). The objective is to develop a multiplex Luminex
test allowing both serotyping and differential diagnosis of
VSV. The Luminex technology is based on the principle of
ﬂow cytometry and relies on the use of ﬂuorescent micro-
spheres (“beads”) which can be coupled to biological mac-
romolecules. A batch of beads was coupled to the envelope
glycoprotein of the VSV, serotype NJ (VSV-G-NJ), produced as
recombinant antigen using the baculovirus system and
harboring a C terminus tag MAT. The coupled beads were
incubated with positive equine sera and the antigen/antibody
complexes were revealed using biotinylated anti-species
antibody and streptavidin-phycoerythrin. Results were
analyzed on the Luminex200 platform. Median ﬂuorescence
intensity (MFI) values were measured and normalized. VNT
were conducted per the OIE manual for terrestrial animals,
using the alternative protocol (virus at 100 TCID50 /25mL).
Efﬁciency of antigen/bead coupling was assessed using a
monoclonal antibody speciﬁc to the MAT tag. Speciﬁcity of
the coupling was veriﬁed using a panel of well characterized
positive bovine VSV-NJ- or VSV-IND sera. The protocol was
then optimized for equine sera. A prototype test was thus
developed, with a cut off value determined using a panel of
100 naive horse sera, in two independent experiments. This
prototype was evaluated on a panel of positive equine sera.
VNT was performed on the same panel. Results obtained
show a good correlation between Luminex, VNT and C ELISA
analyses. A ﬁrst step in developing a Luminex-based sero-
logical test for VS diagnostic was reached, using the VSV-G
protein-NJ. Similar work is underway using a recombinant
VSV-G-IND protein and a duplex test is under development.
Bead sets coupled to these VSV-G proteins may also be
combined to bead batches developed in our laboratory for
FMD serological diagnosis with the aim to offer a differential
diagnostic VS/FMD in cattle. The sensitivity and speciﬁcity of
these luminex prototypes will also be compared to those
obtained with the VNT reference method.108
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